✦ LIBER ✦

Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin

✍ Scribed by Hidenori Toyoda, Takashi Kumada, Noritomo Shimada…

Book ID: 120678898
Publisher: BioMed Central
Year: 2012
Tongue: English
Weight: 210 KB
Volume: 12
Category: Article
ISSN: 1471-2334
DOI: 10.1186/1471-2334-12-324

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High ability to predict the treatment ou

High ability to predict the treatment outcome of peginterferon and ribavirin combination therapy based on the reduction in HCV RNA levels at 4

✍ Hidenori Toyoda; Takashi Kumada; Seiki Kiriyama; Makoto Tanikawa; Yasuhiro Hisan 📂 Article 📅 2010 🏛 Springer Japan 🌐 English ⚖ 266 KB

Predicting treatment outcome following 2

Predicting treatment outcome following 24 weeks peginterferon α-2a/ribavirin therapy in patients infected with HCV genotype 1: Utility of HCV-RNA at day 0, day 22, day 29, and week 6

✍ Esther Lukasiewicz; Kristoffer Hellstrand; Johan Westin; Carlo Ferrari; Avidan U 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

We sought to validate FIB-4 using data retrospectively collected from treatment-naive HIV/HCV patients. The original model was adapted in order to use AST and ALT levels expressed as times the upper limit of normality (ϫULN), as follows: (age [yr] ϫ AST [ϫULN]) ϫ 10/((PLT [10 9 /l]) ϫ (ALT [ϫULN]) 1

315 HCV-RNA DECLINE IN THE FIRST 48 HOUR

315 HCV-RNA DECLINE IN THE FIRST 48 HOURS IDENTIFIES HCV MONOINFECTED AND HCV/HIV COINFECTED PATIENTS WITH RVR AT WEEK 4 OF PEGINTERFERON-ALPHA-2A/RIBAVIRIN THERAPY

✍ J.E. Arends; J. Cohen Stuart; L.C. Baak; M.E. van der Ende; K.J. van Erpecum; G. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 94 KB

Mutation frequency of NS5A in patients v

Mutation frequency of NS5A in patients vertically infected with HCV genotype 1 predicts sustained virological response to peginterferon alfa-2b and ribavirin combination therapy

✍ A. C. W. Jenke; S. Moser; V. Orth; M. Zilbauer; P. Gerner; S. Wirth 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB

Predictive value of early viral dynamics

Predictive value of early viral dynamics during peginterferon and ribavirin combination therapy based on genetic polymorphisms near the IL28B gene in patients infected with HCV genotype 1b

✍ Hidenori Toyoda; Takashi Kumada; Toshifumi Tada; Kazuhiko Hayashi; Takashi Honda 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 242 KB 👁 1 views

## Abstract A study was carried out to determine whether early viral dynamics retain prediction of the outcome of peginterferon (PEG‐IFN) and ribavirin combination therapy based on different genetic polymorphisms near the __IL28B__ gene, the strongest baseline predictor of response to this therapy.

A matched case-controlled study of 48 an

A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response

✍ Norio Akuta; Fumitaka Suzuki; Miharu Hirakawa; Yusuke Kawamura; Hiromi Yatsuji; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 1 views

## Abstract Substitution of amino acid (aa) 70 and 91 in the core region of HCV genotype 1b is a useful pretreatment predictor of efficacy of 48‐week peginterferon (PEG‐IFN) plus ribavirin (RBV) therapy. Here, we determined the efficacy of 72‐week PEG‐IFN/RBV and the predictive factors to such ther